Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The VALIDATE Network, a community of over 400 researchers based in more than 200 research institutions in 63 countries, will today launch the “BCG100 Programme” marking the centenary of the Bacille Calmette-Guérin Vaccine for tuberculosis.

3D illustration of bacteria mycobacterium tuberculosis

The Bacille Calmette-Guérin (BCG) vaccine is the first, and still a century later, only vaccine approved for humans that protects against tuberculosis.

On 18 July 1921 at the Hôpital de la Charité in Paris, a newborn infant, whose mother had died of tuberculosis that same morning, received a dose of an experimental vaccine called Bacille Calmette- Guérin. This young child would be the first human to receive the BCG vaccine, which, over the coming century, would be administered to billions of people across the planet, saving tens of millions of lives.

Starting on World TB Day, 24 March 2021, VALIDATE's BCG100 programme will consist of public events, talks with school students from around the world, a social media campaign, a series of computer games and other online activities with the aim of educating the public about the science and history behind vaccinations.

VALIDATE also hopes to draw attention to the work researchers are doing today to improve or replace the lifesaving but flawed BCG vaccine. BCG100 officially launches with the ‘BCG Then and Now’ online lecture by Professor Helen McShane (University of Oxford) and Professor Paul Fine (London School of Hygiene and Tropical Medicine). Taking place at 6pm GMT, 24 March 2021, the talk will cover the initial development of the vaccine, moving through to the modern-day challenges in the fight against TB and the future challenges researchers face in replacing the enduring BCG vaccine.

Read the full story on the University of Oxford website.

Similar stories

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.